A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

3162 Background: 15 Belgian oncology centers are participating in an open-label Phase II trial of gefitinib (IRESSA) 500 mg/day in patients (pts) with advanced epidermal growth factor receptor-positive solid tumors who had failed ≥1 previous chemotherapy regimen and had no further chemotherapy treatment options. Here we report interim data. Methods: Pts received gefitinib 500 mg/day until disease progression. Objective tumor assessments, by RECIST, were made every 8 weeks and confirmed by repeat assessments ≥4 weeks later. Disease control rate (DCR) was defined as objective response (confirmed complete response or partial response [PR]) plus stable disease (SD) for ≥8 weeks. All adverse events (AEs) were reported and assessed by NCI-CTC version 2.0. Results: 193 pts have been enrolled with pancreatic cancer [21%], cervical cancer (CC) [19%], ovarian cancer (OC) [17%], sarcoma (S) [12%], cancer of unknown primary origin (U) [10%], hepatocellular carcinoma (HC) [9%], bladder cancer (BC) [7%], and endometria...